Cancer News and Research

Latest Cancer News and Research

Study results show calcium consumption increases prostate cancer risk in Chinese

Among Chinese men, calcium consumption — even at relatively low levels and from non-dairy food sources such as soy, grains and green vegetables — may increase prostate cancer risk, according to results published in Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2010

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

DARA BioSciences, Inc. today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement as set forth in NASDAQ Listing Rule 5550(a)(2). On May 26, 2010, the Company's closing bid price was $3.58 per share, the tenth consecutive day it had been above $1 per share.

2 Jun 2010

Businesses fret penalties, seek opportunities in health overhaul

Some small businesses may get financial help as part of the health overhaul that could cover up to 35 percent of business's premium costs for insuring employees in the form of new tax credits, Kaiser Health News explains in a consumer column.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

GE Healthcare, a pioneer in digital mammography, today announced the introduction of an innovative technology to aid in breast cancer diagnosis. GE Healthcare's new SenoBright Contrast Enhanced Spectral Mammography technology reduces ambiguity in mammography results, enabling physicians to detect and diagnose cancer with more confidence - even in the densest part of the breast tissue more rapidly and accurately.

1 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".

1 Jun 2010

MediSapiens completes $1M seed round investment for personalized cancer medicine software

MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

1 Jun 2010

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

A compound found in sunless tanning spray may help to heal wounds following surgery, according to new results published by plastic surgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City and biomedical engineers at Cornell University in Ithaca, N.Y., where the novel compound was developed.

1 Jun 2010

Alcohol consumption in Portugal represents heavy economic burden for that country's health system

The World Health Organization has estimated that 3.2 percent of the "burden of disease" around the world is attributable to the consumption of alcohol. Portugal is currently ranked eighth in the world in alcohol consumption. A new study has found alcohol consumption in Portugal represents a heavy economic burden for that country's health system.

1 Jun 2010

University of California scientists identify new kinase that regulates cell proliferation, migration

Scientists at the University of California, San Diego have identified a previously unknown kinase that regulates cell proliferation, shape and migration, and may play a major role in the progression or metastasis of cancer cells.

1 Jun 2010

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

1 Jun 2010

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

EpiCept Corporation today provided an update on the post-approval commitments requested by the European Medicines Agency as part of its marketing authorization for Ceplene (histamine dihydrochloride). Ceplene is approved in the EU for remission maintenance and prevention of relapse in adults with Acute Myeloid Leukemia in first complete remission.

1 Jun 2010

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Dendreon Corporation today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

1 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Study results show calcium consumption increases prostate cancer risk in Chinese

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

Businesses fret penalties, seek opportunities in health overhaul

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

New technique transforms iPS cells into natural tumor killers

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Europe spends just 5% of total cancer research funds on metastases

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

GE Healthcare introduces new CESM technology to aid in breast cancer diagnosis

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

MediSapiens completes $1M seed round investment for personalized cancer medicine software

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

Alcohol consumption in Portugal represents heavy economic burden for that country's health system

University of California scientists identify new kinase that regulates cell proliferation, migration

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

EpiCept provides update on post-approval commitments requested by EMA for Ceplene

Dendreon announces data presentation from 4 PROVENGE clinical trials at 105th AUA annual meeting

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in